Safety Profile of Biological Medicines as Compared with Non-Biologicals: An Analysis of the Italian Spontaneous Reporting System Database

Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases

(2013) Niels S. Vermeer et al.   DRUG SAFETY

EU’s New Pharmacovigilance Legislation: Considerations for Biosimilars

(2013) Begoña Calvo et al.   DRUG SAFETY

Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review

(2012) E. Lu et al.   NEUROLOGY

On analyzing therapeutic ineffectiveness reports

(2012) Joshua J. Gagne et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy

(2011) Magnhild Sandberg-Wollheim et al.   Multiple Sclerosis Journal

Mapping the Safety Profile of Biologicals

(2010) Thijs J. Giezen et al.   DRUG SAFETY

Pharmacovigilance of Biopharmaceuticals

(2009) Thijs J. Giezen et al.   DRUG SAFETY

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

(2009) Anja Strangfeld   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

TNF-?? Inhibitors and Leukaemia: International Pharmacovigilance Reports

(2008) Ronald H B Meyboom et al.   DRUG SAFETY

Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union

(2008)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION